Herantis Pharma Plc is planning a directed share issue and prepares for a contemplated secondary listing on the First North Stockholm marketplace

Herantis Pharma Plc ("Herantis" or the "Company") is planning a directed share issue to a limited number of investors and the Company's directors (the "Private Placement") for the purposes of financing the development necessary for the business of the Company such as activities related to preparations for the Phase 2 and Phase 3 clinical studies of CDNF and Lymfactin®, and for the preclinical development of a non-invasive CDNF. By strengthening its financial standing, the Company would also seek to improve its negotiating position in potential partnership negotiations concerning the co-development or commercialization of CDNF and Lymfactin®. The purpose of the investments by the Company's directors is also to commit said persons to the Company.

The possible Private Placement would not include a public offering of the shares.

In addition to a possible share issue, the company is preparing for a contemplated secondary listing of its shares on the First North Stockholm marketplace, which is expected to take place in 2019 (the "Secondary Listing"). The Company will consider a public offering of a limited number of its shares in conjunction with the Secondary Listing.

The purpose of the possible share issue in connection with the Secondary Listing would be to secure the sufficiency of working capital until approximately the end of 2020.

Herantis is today issuing a notice to convene an Extraordinary General Meeting. The Company's Board of Directors will propose to the Extraordinary General Meeting that it authorize the Board of Directors to decide on an issue of up to 1,500,000 new or treasury shares to facilitate the potential Private Placement and the potential Secondary Listing.

Both the p